Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665887 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL665970 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL667411 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL26112778 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL26112782 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL3168997 | 0.82 | — | — | |
| SCHEMBL2102406 | 0.81 | HRH3 (0.38) | SMN1; SMN2OPRL1 | |
| SCHEMBL14862483 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| Ammonia Solution, Strong SCHEMBL4295582 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL9425142 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939322-B2 | Method for producing tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-26 | — | — | US | claimed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | claimed |
| EP-3921319-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | claimed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2020160710-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | claimed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | claimed |
| CN-110662745-A | Pyrrolopyridine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating protein kinase-associated diseases comprising the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2020-01-07 | — | — | CN | claimed |
| WO-2018174650-A9 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | 재단법인 대구경북첨단의료산업진흥재단 | 2020-01-02 | — | — | WO | claimed |
| EP-3110812-B1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORP (US) | 2019-04-10 | — | — | EP | claimed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2006053255-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-6821970-B2 | USEFUL FOR TREATING DISEASES WHEREIN MODULATION OF 5-HT ACTIVITY IS DESIRED; NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | claimed |
| EP-0781277-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1997-07-02 | — | — | EP | claimed |
| WO-1996008480-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1996-03-21 | — | — | WO | claimed |
| EP-0107261-A2 | (2-((Nitropyridinyl)amino)phenyl)arylmethanones and salts, their use in medicine, pharmaceutical compositions containing them and their use in the preparation of (2-((aminopyridinyl)amino)phenyl)arylmethanones and pyrido(1,4)benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | SMN1; SMN2 4570/4885L3MBTL3 2679/4885L3MBTL1 2882/4885 |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | BET1, PGGT1B, TMPO | SMN1; SMN2 4756/4885L3MBTL3 4885/4885L3MBTL1 4879/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | SMN1; SMN2 1880/4885L3MBTL3 3564/4885L3MBTL1 3028/4885 |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | CYP11B1, ROR1, RET | SMN1; SMN2 3101/4885L3MBTL3 4861/4885L3MBTL1 4708/4885 |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | SMN1; SMN2 884/4885L3MBTL3 3361/4885L3MBTL1 3110/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | SMN1; SMN2 2173/4885L3MBTL3 1385/4885L3MBTL1 1887/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | SMN1; SMN2 4874/4885L3MBTL3 4871/4885L3MBTL1 4865/4885 |
| US-11939322-B2 | Method for producing tetracyclic compound | CYP1B1, CYP4B1, PAICS | SMN1; SMN2 1226/4885L3MBTL3 3705/4885L3MBTL1 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.